<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST-elevation myocardial infarction</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST-elevation myocardial infarction</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST-elevation myocardial infarction</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">C Michael Gibson, MS, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph P Carrozza, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Roger J Laham, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Donald Cutlip, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 11, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Coronary artery reperfusion after acute ST-elevation myocardial infarction (STEMI) improves patient outcomes. Reperfusion can be achieved by primary percutaneous coronary intervention (PCI) or fibrinolysis. Primary PCI is preferred if it can be performed within 90 minutes (from arrival to the emergency department of the primary PCI center) to 120 minutes (from arrival of transferring hospital). (See  <a class="medical medical_review" href="/z/d/html/80.html" rel="external">"Acute ST-elevation myocardial infarction: Selecting a reperfusion strategy"</a>.)</p><p>Issues related to suboptimal reperfusion after primary PCI (including no reflow) will be reviewed here (see <a class="local">'No reflow'</a> below). Other issues related to primary PCI are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/72.html" rel="external">"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome"</a> and  <a class="medical medical_review" href="/z/d/html/15358.html" rel="external">"Primary percutaneous coronary intervention in acute ST-elevation myocardial infarction: Periprocedural management"</a> and  <a class="medical medical_review" href="/z/d/html/80.html" rel="external">"Acute ST-elevation myocardial infarction: Selecting a reperfusion strategy"</a>.)</p><p class="headingAnchor" id="H1449592703"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>For patients who have undergone primary PCI, suboptimal reperfusion of the distal myocardial bed is defined as a Thrombolysis in Myocardial Infarction flow grade &lt;3  (<a class="graphic graphic_table graphicRef51941" href="/z/d/graphic/51941.html" rel="external">table 1</a>). This angiographic assessment is made by evaluating the flow of contrast material beyond the site of PCI into the distal vessel.</p><p class="headingAnchor" id="H2"><span class="h1">CAUSES</span><span class="headingEndMark"> — </span>Suboptimal reperfusion after primary PCI may be caused by either epicardial coronary artery obstruction or no reflow/microvascular dysfunction.</p><p>Primary PCI with stent placement leads to a patent coronary artery at the site of proximal obstruction in more than 95 percent of cases. However, epicardial obstruction may be due to:</p><p class="bulletIndent1"><span class="glyph">●</span>Persistent stenosis</p><p class="bulletIndent1"><span class="glyph">●</span>Persistent thrombus</p><p class="bulletIndent1"><span class="glyph">●</span>Intramural hematoma</p><p class="bulletIndent1"><span class="glyph">●</span>Side-branch occlusion</p><p class="bulletIndent1"><span class="glyph">●</span>Epicardial coronary artery spasm</p><p></p><p>In the 232 patients (7 percent) with a final Thrombolysis in Myocardial Infarction flow grade ≤2 in the PAMI trials, persistent stenosis &gt;50 percent, thrombus, and dissection were present in 28, 26, and 40 percent, respectively [<a href="#rid1">1</a>]. These complications of PCI are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1562.html" rel="external">"Periprocedural complications of percutaneous coronary intervention", section on 'Coronary artery complications'</a>.)</p><p>Microvascular dysfunction/no reflow are discussed below. (See <a class="local">'Mechanisms'</a> below.)</p><p class="headingAnchor" id="H3"><span class="h1">CLINICAL RISK FACTORS</span><span class="headingEndMark"> — </span>Risk factors for a final Thrombolysis in Myocardial Infarction (TIMI) flow grade ≤2 after PCI include  (<a class="graphic graphic_table graphicRef51941" href="/z/d/graphic/51941.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Age ≥70 years</p><p class="bulletIndent1"><span class="glyph">●</span>Diabetes</p><p class="bulletIndent1"><span class="glyph">●</span>Longer time to reperfusion</p><p class="bulletIndent1"><span class="glyph">●</span>Pre-PCI TIMI flow grade ≤1</p><p class="bulletIndent1"><span class="glyph">●</span>Left ventricular ejection fraction &lt;50 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Saphenous vein culprit lesion [<a href="#rid2">2</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Large thrombus burden</p><p class="bulletIndent1"><span class="glyph">●</span>Left anterior descending coronary artery PCI</p><p></p><p>Patients who present with heart failure also appear to be more likely to have suboptimal reperfusion after primary PCI. In a report of 1548 patients, there was a significant correlation between Killip class  (<a class="graphic graphic_table graphicRef65592" href="/z/d/graphic/65592.html" rel="external">table 2</a>) and postprocedural TIMI flow grade ≤2 [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/88759.html" rel="external">"Risk factors for adverse outcomes after ST-elevation myocardial infarction", section on 'Killip class'</a>.)</p><p>A clinical correlate of suboptimal reperfusion is incomplete ST-segment elevation resolution. In a series of 1005 consecutive patients with STEMI who were treated with primary PCI, 42 percent had incomplete ST-segment elevation resolution (defined as ≥1 mm ST-segment elevation after PCI) [<a href="#rid4">4</a>]. Independent predictors of incomplete resolution were anterior MI, Killip class 3 to 4  (<a class="graphic graphic_table graphicRef65592" href="/z/d/graphic/65592.html" rel="external">table 2</a>), and TIMI flow grade &lt;2 before PCI and &lt;3 (3 represents normal flow) after PCI. Incomplete ST-segment elevation resolution was an independent predictor of mortality and also predicts adverse outcomes in patients treated with fibrinolytic therapy. (See  <a class="medical medical_review" href="/z/d/html/91.html" rel="external">"Diagnosis and management of failed fibrinolysis or threatened reocclusion in acute ST-elevation myocardial infarction", section on 'Primary failure'</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">NO REFLOW</span><span class="headingEndMark"> — </span>Some patients do not recover normal myocardial perfusion distal to the site of proximal obstruction despite the absence of epicardial vessel obstruction. This phenomenon is called "no reflow" and is a predictor of worse outcome.</p><p>The no-reflow phenomenon is defined as a profound reduction in antegrade coronary blood flow (Thrombolysis in Myocardial Infarction [TIMI] flow grade ≤2 ) despite proximal vessel patency and the absence of dissection, spasm, or distal macroembolus, which is defined as a distal angiographic filling defect with an abrupt "cutoff" in one of the peripheral coronary artery branches of the infarct-related vessel, distal to the site of PCI [<a href="#rid5">5-7</a>]. It is presumed to reflect microvascular dysfunction and appears to be more common in patients with diabetes, as well as the risk factors presented above [<a href="#rid8">8,9</a>] (see <a class="local">'Clinical risk factors'</a> above). In addition, the likelihood of severe microvascular dysfunction is increased with a longer time from symptom onset to reperfusion [<a href="#rid10">10,11</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Incidence</span><span class="headingEndMark"> — </span>Attainment of TIMI 3 flow  (<a class="graphic graphic_table graphicRef51941" href="/z/d/graphic/51941.html" rel="external">table 1</a>) is much more common with primary PCI than fibrinolysis. The incidence of no reflow has varied widely and depends in part upon the method used for detection and possibly interobserver variability. Using the criterion of TIMI flow grade ≤2 without macrovascular obstruction, the incidence of no reflow during PCI has ranged from 4 to 7 percent in some studies [<a href="#rid1">1,12</a>] and 12 to 25 percent in others [<a href="#rid13">13,14</a>]. Even higher rates have been noted with other modalities that can assess microvascular flow: 29 percent using the TIMI myocardial perfusion grade [<a href="#rid15">15</a>] and 34 to 39 percent using myocardial contrast echocardiography [<a href="#rid10">10,16</a>]. (See <a class="local">'Detection'</a> below.)</p><p>The likelihood of no reflow correlates with the severity of myocardial damage during the infarct and TIMI flow. Reported predictors of no reflow are Killip class, the number of Q waves, the wall motion score on echocardiogram, and the presence of TIMI flow grade 0 on the initial coronary angiogram [<a href="#rid3">3,17</a>]. (See  <a class="medical medical_review" href="/z/d/html/72.html" rel="external">"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome", section on 'Time from symptom onset'</a>.)</p><p>On the other hand, preinfarction angina appears to attenuate the no-reflow phenomenon, suggesting a protective effect from ischemic preconditioning [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/z/d/html/1487.html" rel="external">"Myocardial ischemic conditioning: Pathogenesis"</a> and  <a class="medical medical_review" href="/z/d/html/1489.html" rel="external">"Myocardial ischemic conditioning: Clinical implications"</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Mechanisms</span><span class="headingEndMark"> — </span>Multiple factors probably contribute to no reflow, all of which ultimately result in microvascular dysfunction. These include distal embolization of plaque and/or thrombus, myocardial necrosis, reperfusion injury resulting from oxygen free radical production, release of active tissue factor from the dissected plaque, and vasoconstriction secondary to alpha adrenergic tone, thromboxane A2, or serotonin released from platelets [<a href="#rid5">5,16,18-21</a>].</p><p>The role of distal embolization was suggested in an intravascular ultrasound study that evaluated total plaque volume before and after primary PCI [<a href="#rid22">22</a>]. Plaque volume decreased after the procedure in all patients, but a significantly greater decrease in plaque volume was seen in patients with inadequate reflow. Plaque volume after PCI also correlated with the corrected TIMI frame count.</p><p>Similar findings have been noted in patients with stable angina undergoing PCI. (See  <a class="medical medical_review" href="/z/d/html/1562.html" rel="external">"Periprocedural complications of percutaneous coronary intervention", section on 'Distal embolization'</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Detection</span><span class="headingEndMark"> — </span>In clinical studies using angiographic parameters, no reflow has been defined as a TIMI flow grade (a visual estimate) ≤2  (<a class="graphic graphic_table graphicRef51941" href="/z/d/graphic/51941.html" rel="external">table 1</a>) in the absence of macrovascular obstruction [<a href="#rid13">13,14</a>]. However, microvascular perfusion may also be reduced in patients with TIMI flow grade 3 and may occur concomitantly with epicardial vessel obstruction.</p><p>We rarely use the following methods to assess microvascular perfusion:</p><p class="bulletIndent1"><span class="glyph">●</span>TIMI frame count, which is the number of cine-frames required for the contrast material to reach a distal coronary landmark or the TIMI myocardial perfusion grade (or myocardial blush grade) [<a href="#rid15">15,23,24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A coronary Doppler flow wire can be used to assess no reflow. Doppler flow measurements reveal a characteristic pattern of both systolic retrograde flow and rapid deceleration of diastolic flow in vessels with no reflow [<a href="#rid25">25-27</a>]. In comparison, a residual stenosis is characterized by slow diastolic flow velocity, prolonged diastolic deceleration time, and a smaller diastolic/systolic flow velocity ratio. (See  <a class="medical medical_review" href="/z/d/html/1514.html" rel="external">"Clinical use of coronary artery pressure flow measurements"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Myocardial contrast echocardiography [<a href="#rid16">16,28</a>] and contrast-enhanced cardiovascular magnetic resonance [<a href="#rid10">10,29,30</a>] have been used to detect no reflow. Both have the advantage of also defining the extent of myocardium affected. (See  <a class="medical medical_review" href="/z/d/html/5314.html" rel="external">"Clinical utility of cardiovascular magnetic resonance imaging", section on 'Infarct detection and sizing'</a>.)</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Prevention</span><span class="headingEndMark"> — </span>Possible approaches to preventing the no-reflow phenomenon include the use of thrombectomy, distal embolic protection, direct stenting, systemic infusion of glycoprotein (GP) IIb/IIIa inhibitors, and intracoronary infusion of vasodilating or antithrombotic/thrombolytic agents. Among these, only direct stenting has been shown to improve outcomes.</p><p class="headingAnchor" id="H4029580299"><span class="h3">Direct stenting</span><span class="headingEndMark"> — </span>We perform direct stenting without predilation of the culprit lesion when possible for multiple reasons. It may reduce or prevent no reflow. The role of direct stenting in STEMI patients is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/15358.html" rel="external">"Primary percutaneous coronary intervention in acute ST-elevation myocardial infarction: Periprocedural management", section on 'Direct stenting'</a>.)</p><p class="headingAnchor" id="H9"><span class="h3">Thrombectomy</span><span class="headingEndMark"> — </span>For patients undergoing primary PCI, we do not routinely perform manual thrombectomy (eg, thrombus aspiration, aspiration thrombectomy) [<a href="#rid31">31</a>]. However, there may be occasional instances in which clinical and angiographic characteristics make thrombectomy a reasonable choice.</p><p>The TOTAL [<a href="#rid32">32</a>], TASTE [<a href="#rid33">33,34</a>], and TAPAS [<a href="#rid35">35,36</a>] trials are the largest and best performed studies of manual thrombectomy in STEMI. These studies randomly assigned patients to routine manual thrombectomy followed by PCI or PCI alone. A 2017 individual patient meta-analysis of these three trials (n = 18,306) found no difference in the rates of cardiovascular death at 30 days (2.4 versus 2.9 percent; hazard ratio 0.84, 95% CI 0.70-1.01) [<a href="#rid37">37</a>]. Similarly, there was no difference at 30 days in the rate of stroke or transient ischemic attack (0.8 versus 0.5 percent; odds ratio 1.43, 95% CI 0.98-2.10).</p><p>With regard to mechanical (rheolytic) thrombectomy, the results of randomized trials do not show benefit in the aggregate [<a href="#rid38">38-41</a>]. A 2013 meta-analysis included seven trials (n = 1598) comparing mechanical thrombectomy to conventional PCI [<a href="#rid36">36</a>]. There was no significant difference between the two strategies in the incidence of death or major adverse cardiovascular events, but there was a trend toward a higher rate of all strokes with the former (1.3 versus 0.4 percent; risk ratio 2.74, 95% CI 0.93-8.01).</p><p class="headingAnchor" id="H10"><span class="h3">Distal embolic protection devices</span><span class="headingEndMark"> — </span>We do not use a distal embolic protection device as routine adjunctive therapy to primary PCI with stenting in patients with acute STEMI in the native circulation. Distal embolic protection devices are increasingly used with PCI in saphenous vein grafts due to the substantial potential for embolization of both thrombus and atheromatous material. (See  <a class="medical medical_review" href="/z/d/html/1565.html" rel="external">"Coronary artery bypass graft surgery: Prevention and management of vein graft stenosis", section on 'Embolic protection devices'</a>.)</p><p>The efficacy of a distal embolic protective device in acute STEMI was addressed in the multicenter EMERALD trial of 501 patients who presented within six hours of symptom onset and underwent primary PCI or rescue intervention after failed fibrinolysis in native coronary arteries [<a href="#rid42">42</a>]. The patients were randomly assigned to primary PCI alone or with a distal occlusion balloon and aspiration distal microcirculation system (eg, GuardWire, PercuSurge/Medtronic). Among the patients assigned to distal protection, aspiration was performed in 97 percent, and visible debris was retrieved from 73 percent.</p><p>Despite the removal of debris, there was <strong>no difference</strong> between the two groups in terms of the coprimary endpoints of ST-segment resolution at 30 minutes (63 versus 62 percent) and left ventricular infarct size (12.0 versus 9.5 percent). In addition, the secondary endpoint of major adverse cardiac events at six months was equivalent in the two groups (10 versus 11 percent). The lack of benefit persisted when only the 83 percent of patients undergoing primary PCI (not rescue) were evaluated and was seen in all subsets.</p><p>A lack of benefit was also noted in two later randomized trials (PROMISE and DEDICATION), which were of similar design but used a different distal embolic protection device (FilterWire) [<a href="#rid43">43,44</a>].</p><p>Potential mechanisms for the lack of benefit in these trials include smaller embolic burden than seen in saphenous vein grafts, embolization caused by crossing the lesion with the embolic protection device, delayed reperfusion due to the occlusive nature of the device, other nonembolic causes of microcirculatory dysfunction, difficulty protecting side branches, difficulty in detecting benefit against the background of established myocardial infarction, and embolization of vasoconstrictor materials not captured by the device [<a href="#rid45">45-47</a>].</p><p class="headingAnchor" id="H5881390"><span class="h3">Systemic glycoprotein IIb/IIIa inhibitors</span><span class="headingEndMark"> — </span>Among patients undergoing primary PCI for acute STEMI, we do not routinely use systemic GP IIb/IIIa inhibitors for prevention of no reflow. (See  <a class="medical medical_review" href="/z/d/html/94.html" rel="external">"Acute ST-elevation myocardial infarction: Antiplatelet therapy", section on 'Intravenous agents'</a>.)</p><p class="headingAnchor" id="H12"><span class="h3">Intracoronary infusions</span><span class="headingEndMark"> — </span>Intracoronary infusions of <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">adenosine</a>, <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a>, streptokinase, or abciximab have been evaluated in small studies for their ability to improve myocardial reperfusion, prevent reperfusion injury, and salvage ischemic myocardium at the time of primary PCI. None of these agents is associated with a convincing improvement in outcomes (either myocardial flow or clinical) [<a href="#rid48">48</a>].</p><p>A 2013 systematic review and meta-analysis of nine small randomized trials of <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">adenosine</a> and one of <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a> found no evidence that either agent reduced short-term, all-cause mortality or nonfatal MI. In addition, there was an increase in the risk of adverse effects such as bradycardia or hypotension with adenosine [<a href="#rid49">49</a>]. This may reflect underpowering to demonstrate a treatment effect rather than a proven lack of efficacy. Moreover, the dihydropyridine calcium blocker <a class="drug drug_general" data-topicid="9697" href="/z/d/drug information/9697.html" rel="external">nicardipine</a> is used increasingly since bradycardia is avoided.</p><p class="headingAnchor" id="H15"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>The optimal management strategy for no reflow after the establishment of proximal coronary artery patency with PCI is unknown in part because no therapy has been shown to clearly improve outcomes.</p><p>Intracoronary vasodilator therapy has been evaluated; it has not been shown to improve clinical outcomes [<a href="#rid14">14,50-53</a>]. In small series, intracoronary <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a> was used with apparent success in treating no reflow [<a href="#rid14">14,54</a>]. Intracoronary <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">nitroprusside</a> at doses of 50 to 200 mcg has also shown promising results when given alone or with intracoronary <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">adenosine</a> [<a href="#rid51">51-53,55</a>]. In the absence of hypotension or when no reflow persists as a potential contributor to hypotension, we administer intracoronary vasodilators, favoring calcium channel blockers (eg, verapamil, <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">diltiazem</a>, or <a class="drug drug_general" data-topicid="9697" href="/z/d/drug information/9697.html" rel="external">nicardipine</a>) or nitroprusside. Improved effectiveness may be achieved with administering the vasodilator agents to the distal vessel via a microcatheter or angioplasty balloon.</p><p>For patients with hypotension and/or hypoperfusion, intravenous vasopressors, inotropic agents, and ventricular support devices such as intraaortic balloon pump or Impella may be of benefit. (See  <a class="medical medical_review" href="/z/d/html/83.html" rel="external">"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction", section on 'Summary and Recommendations'</a>.)</p><p class="headingAnchor" id="H2568835205"><span class="h3">Antithrombotic/fibrinolytic therapies</span><span class="headingEndMark"> — </span>We do not routinely use intracoronary GP IIb/IIIa inhibitors or fibrinolytic drugs for the treatment of impaired microvascular perfusion. While there is no direct evidence of benefit, we believe it is reasonable to administer an intracoronary GP IIb/IIIa inhibitor to patients with evidence of no reflow (or giant thrombus).</p><p>Intracoronary GP IIb/IIIa inhibitors and streptokinase have been evaluated in randomized trials for their ability to improve microvascular perfusion in patients undergoing primary PCI. (See <a class="local">'Systemic glycoprotein IIb/IIIa inhibitors'</a> above.)</p><p>The following are representative trials of intracoronary abciximab from the stent era:</p><p class="bulletIndent1"><span class="glyph">●</span>In a trial of 534 patients randomly assigned to either intracoronary or intravenous bolus of abciximab after primary PCI with thrombus aspiration, there was no significant difference in the incidence of complete ST-segment resolution, which was the primary endpoint (64 versus 62 percent, respectively) [<a href="#rid56">56</a>]. However, the secondary endpoints of myocardial blush grade and enzymatic infarct size were better in the intracoronary infusion group.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a trial of 154 patients randomly assigned to either intravenous or intracoronary bolus of abciximab, both of which were followed by a 12-hour infusion, the primary endpoint of median infarct size at two days, as determined by magnetic resonance imaging (MRI), was significantly reduced in the group treated with intracoronary abciximab (15.1 versus 23.4 percent) [<a href="#rid57">57</a>]. The extent of microvascular obstruction seen on MRI and early ST-segment resolution were also significantly improved. There was also a trend toward fewer major adverse cardiovascular events. (See  <a class="medical medical_review" href="/z/d/html/5314.html" rel="external">"Clinical utility of cardiovascular magnetic resonance imaging", section on 'Infarct detection and sizing'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A third trial of 50 patients evaluated the efficacy of intracoronary abciximab delivered either through the guiding catheter or a dedicated perfusion catheter at the site of occlusion [<a href="#rid58">58</a>]. Local intracoronary delivery significantly reduced the thrombus score after PCI, as determined by optical coherence tomography (4 versus 34 percent).</p><p></p><p>Given these limited data, abciximab or other GP IIb/IIIa inhibitors have rarely been used for intracoronary administration for treatment of no reflow. Abciximab is no longer available. The possible efficacy of low-dose intracoronary streptokinase (250,000 units) was compared with no additional therapy in a trial of 41 patients who had undergone successful PCI [<a href="#rid59">59</a>]. The TIMI frame count and multiple measures of microvascular perfusion (eg, coronary flow reserve, index of microvascular resistance, and collateral flow index) were significantly better in the streptokinase group at 48 hours. However, there was no significant difference between the two groups in left ventricular size or function at six months.</p><p class="headingAnchor" id="H2926604238"><span class="h3">Vasodilator therapies</span><span class="headingEndMark"> — </span>Intracoronary vasodilators such as <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">adenosine</a>, <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">nitroprusside</a>, and <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a> are of unproven benefit when given for slow coronary flow in STEMI, and we rarely use them. However, it is possible that the absence of benefit noted in studies is due to small size or suboptimal design. Better clinical outcomes are seen in patients with improvement in coronary flow, and there is general agreement within the interventional community that coronary flow often improves after the infusion of vasodilators such as calcium channel blockers, sodium nitroprusside, and adenosine.</p><p class="headingAnchor" id="H16"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The 4 to 7 percent of patients who do not achieve Thrombolysis in Myocardial Infarction (TIMI) 3 (normal) flow  (<a class="graphic graphic_figure graphicRef75629 graphicRef70952" href="/z/d/graphic/75629.html" rel="external">figure 1A-B</a>) after primary PCI have worse outcomes  (<a class="graphic graphic_table graphicRef51941" href="/z/d/graphic/51941.html" rel="external">table 1</a>) [<a href="#rid1">1,60</a>]. The magnitude of this effect was illustrated in a report from the PAMI trials [<a href="#rid1">1</a>]. The 232 patients who had a final TIMI flow grade ≤2 after PCI (7 percent of all patients) had significantly higher rates of in-hospital mortality (15 versus 2 percent) and in-hospital major adverse cardiac events (20 versus 6 percent) than those with TIMI 3 flow [<a href="#rid1">1</a>]. At one year, significant differences persisted for mortality (23 versus 5 percent), major adverse cardiac events (37 versus 20 percent), and reinfarction (9 versus 4 percent). A similar significant increase in early (30-day) mortality with TIMI flow ≤2 was noted in the GUSTO-IIb trial (11.7 versus 1.5 percent with TIMI 3 flow) [<a href="#rid60">60</a>].</p><p>A higher rate of adverse outcomes has been noted in other studies in patients with no reflow, regardless of the method of detection [<a href="#rid1">1,3,13,15,16,24,25,29,30,61,62</a>]. These include increases in in-hospital heart failure and mortality (18 versus 0 percent) [<a href="#rid61">61</a>], left ventricular remodeling at six months [<a href="#rid29">29,30,62</a>], and mortality at one year [<a href="#rid3">3</a>]. In a study of 120 patients, the frequency of cardiac mortality (37 versus 10 percent) and the combined cardiac endpoint of recurrent MI, heart failure, malignant arrhythmia, or cardiac mortality continued to increase over a mean follow-up of almost six years [<a href="#rid13">13</a>].</p><p>Both the TIMI myocardial perfusion (TMP) grade and the presence of persistent ST-segment elevation are powerful predictors of prognosis [<a href="#rid63">63,64</a>]. This was illustrated in a review of 253 consecutive high-risk patients who underwent PCI on a native vessel [<a href="#rid24">24</a>]. The following findings were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>A TMP grade on the last angiogram after revascularization of 0/1, indicating little or no tissue perfusion, was associated with a marked increase in mortality compared with TMP grades 2 and 3 at both 30 days (26 versus 10 and 4 percent) and one year (35 versus 13 and 9 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The adjusted odds ratio for cumulative mortality was 2.17 for a TMP grade of 0/1 and 3.61 for persistent ST elevation in more than two leads one hour after PCI.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among patients with a TMP grade of 0/1 or 2, cumulative mortality was much higher in patients who also had persistent ST elevation in more than two leads (47 versus 13 percent). The added value of persistent ST elevation is that it (but not the TMP grade) reflects the size of the area with endangered perfusion.</p><p></p><p>In contrast, the TIMI frame count, another measure of myocardial tissue perfusion, was not an independent predictor of outcomes.</p><p class="headingAnchor" id="H3690844658"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113180.html" rel="external">"Society guideline links: ST-elevation myocardial infarction (STEMI)"</a>.)</p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Primary percutaneous coronary intervention (PCI) in patients with ST-elevation myocardial infarction (STEMI) establishes normal or near-normal antegrade blood flow, as assessed by the Thrombolysis in Myocardial Infarction (TIMI) flow grade 3  (<a class="graphic graphic_table graphicRef51941" href="/z/d/graphic/51941.html" rel="external">table 1</a>), in over 90 percent of cases. Suboptimal reperfusion is said to be present in the 4 to 7 percent of patients who do not achieve normal flow. (See <a class="local">'Definition'</a> above.)</p><p></p><p class="bulletIndent1">Among those STEMI patients with TIMI flow grade &lt;3 after PCI, most cases are due to no reflow, usually attributable to distal microvascular dysfunction, rather than proximal epicardial coronary artery obstruction. (See <a class="local">'Causes'</a> above and <a class="local">'No reflow'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Direct stenting for the primary lesion is the only strategy that has been shown to reduce the risk of no reflow. However, direct stenting may not be possible in some cases. (See <a class="local">'Direct stenting'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For most patients undergoing primary PCI, we suggest not routinely performing thrombus aspiration (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). It is reasonable to use aspiration thrombectomy in patients with a large thrombus burden. (See <a class="local">'Thrombectomy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Distal embolic protection does not appear to protect against no reflow in the native coronary circulation but is effective in saphenous vein grafts. (See <a class="local">'Prevention'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with TIMI flow grade ≤2 due to persistent stenosis, thrombus, dissection, spasm, or distal macroembolism, treatment is directed at correcting the underlying problem. The optimal management strategy for no reflow after the establishment of proximal coronary artery patency with PCI is unknown. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with hypotension and/or hypoperfusion should be treated with the same approach used in other patients with cardiogenic shock following acute MI. (See  <a class="medical medical_review" href="/z/d/html/83.html" rel="external">"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction", section on 'Summary and Recommendations'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Mehta RH, Harjai KJ, Cox D, et al. Clinical and angiographic correlates and outcomes of suboptimal coronary flow inpatients with acute myocardial infarction undergoing primary percutaneous coronary intervention. J Am Coll Cardiol 2003; 42:1739.</a></li><li><a class="nounderline abstract_t">Brodie BR, VerSteeg DS, Brodie MM, et al. Poor long-term patient and graft survival after primary percutaneous coronary intervention for acute myocardial infarction due to saphenous vein graft occlusion. Catheter Cardiovasc Interv 2005; 65:504.</a></li><li><a class="nounderline abstract_t">De Luca G, van 't Hof AW, de Boer MJ, et al. Impaired myocardial perfusion is a major explanation of the poor outcome observed in patients undergoing primary angioplasty for ST-segment-elevation myocardial infarction and signs of heart failure. Circulation 2004; 109:958.</a></li><li><a class="nounderline abstract_t">Brodie BR, Stuckey TD, Hansen C, et al. Relation between electrocardiographic ST-segment resolution and early and late outcomes after primary percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol 2005; 95:343.</a></li><li><a class="nounderline abstract_t">Rezkalla SH, Kloner RA. Coronary No-reflow Phenomenon. Curr Treat Options Cardiovasc Med 2005; 7:75.</a></li><li><a class="nounderline abstract_t">Eeckhout E, Kern MJ. The coronary no-reflow phenomenon: a review of mechanisms and therapies. Eur Heart J 2001; 22:729.</a></li><li><a class="nounderline abstract_t">Henriques JP, Zijlstra F, Ottervanger JP, et al. Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarction. Eur Heart J 2002; 23:1112.</a></li><li><a class="nounderline abstract_t">Prasad A, Stone GW, Stuckey TD, et al. Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction. J Am Coll Cardiol 2005; 45:508.</a></li><li><a class="nounderline abstract_t">Timmer JR, van der Horst IC, de Luca G, et al. Comparison of myocardial perfusion after successful primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction with versus without diabetes mellitus. Am J Cardiol 2005; 95:1375.</a></li><li><a class="nounderline abstract_t">Tarantini G, Cacciavillani L, Corbetti F, et al. Duration of ischemia is a major determinant of transmurality and severe microvascular obstruction after primary angioplasty: a study performed with contrast-enhanced magnetic resonance. J Am Coll Cardiol 2005; 46:1229.</a></li><li><a class="nounderline abstract_t">Kondo M, Nakano A, Saito D, Shimono Y. Assessment of "microvascular no-reflow phenomenon" using technetium-99m macroaggregated albumin scintigraphy in patients with acute myocardial infarction. J Am Coll Cardiol 1998; 32:898.</a></li><li><a class="nounderline abstract_t">Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346:957.</a></li><li><a class="nounderline abstract_t">Morishima I, Sone T, Okumura K, et al. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 2000; 36:1202.</a></li><li><a class="nounderline abstract_t">Piana RN, Paik GY, Moscucci M, et al. Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. Circulation 1994; 89:2514.</a></li><li><a class="nounderline abstract_t">Dibra A, Mehilli J, Dirschinger J, et al. Thrombolysis in myocardial infarction myocardial perfusion grade in angiography correlates with myocardial salvage in patients with acute myocardial infarction treated with stenting or thrombolysis. J Am Coll Cardiol 2003; 41:925.</a></li><li><a class="nounderline abstract_t">Ito H, Okamura A, Iwakura K, et al. Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation 1996; 93:1993.</a></li><li><a class="nounderline abstract_t">Iwakura K, Ito H, Kawano S, et al. Predictive factors for development of the no-reflow phenomenon in patients with reperfused anterior wall acute myocardial infarction. J Am Coll Cardiol 2001; 38:472.</a></li><li><a class="nounderline abstract_t">Hearse DJ, Bolli R. Reperfusion induced injury: manifestations, mechanisms, and clinical relevance. Cardiovasc Res 1992; 26:101.</a></li><li><a class="nounderline abstract_t">Kloner RA, Rude RE, Carlson N, et al. Ultrastructural evidence of microvascular damage and myocardial cell injury after coronary artery occlusion: which comes first? Circulation 1980; 62:945.</a></li><li><a class="nounderline abstract_t">Bonderman D, Teml A, Jakowitsch J, et al. Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque. Blood 2002; 99:2794.</a></li><li><a class="nounderline abstract_t">Gregorini L, Marco J, Kozàkovà M, et al. Alpha-adrenergic blockade improves recovery of myocardial perfusion and function after coronary stenting in patients with acute myocardial infarction. Circulation 1999; 99:482.</a></li><li><a class="nounderline abstract_t">Claessen BE, Maehara A, Fahy M, et al. Plaque composition by intravascular ultrasound and distal embolization after percutaneous coronary intervention. JACC Cardiovasc Imaging 2012; 5:S111.</a></li><li><a class="nounderline abstract_t">Gibson CM, Cannon CP, Murphy SA, et al. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation 2002; 105:1909.</a></li><li><a class="nounderline abstract_t">Haager PK, Christott P, Heussen N, et al. Prediction of clinical outcome after mechanical revascularization in acute myocardial infarction by markers of myocardial reperfusion. J Am Coll Cardiol 2003; 41:532.</a></li><li><a class="nounderline abstract_t">Kawamoto T, Yoshida K, Akasaka T, et al. Can coronary blood flow velocity pattern after primary percutaneous transluminal coronary angioplasty [correction of angiography] predict recovery of regional left ventricular function in patients with acute myocardial infarction? Circulation 1999; 100:339.</a></li><li><a class="nounderline abstract_t">Iwakura K, Ito H, Takiuchi S, et al. Alternation in the coronary blood flow velocity pattern in patients with no reflow and reperfused acute myocardial infarction. Circulation 1996; 94:1269.</a></li><li><a class="nounderline abstract_t">Furber AP, Prunier F, Nguyen HC, et al. Coronary blood flow assessment after successful angioplasty for acute myocardial infarction predicts the risk of long-term cardiac events. Circulation 2004; 110:3527.</a></li><li><a class="nounderline abstract_t">Lepper W, Hoffmann R, Kamp O, et al. Assessment of myocardial reperfusion by intravenous myocardial contrast echocardiography and coronary flow reserve after primary percutaneous transluminal coronary angioplasty [correction of angiography] in patients with acute myocardial infarction. Circulation 2000; 101:2368.</a></li><li><a class="nounderline abstract_t">Taylor AJ, Al-Saadi N, Abdel-Aty H, et al. Detection of acutely impaired microvascular reperfusion after infarct angioplasty with magnetic resonance imaging. Circulation 2004; 109:2080.</a></li><li><a class="nounderline abstract_t">Baks T, van Geuns RJ, Biagini E, et al. Effects of primary angioplasty for acute myocardial infarction on early and late infarct size and left ventricular wall characteristics. J Am Coll Cardiol 2006; 47:40.</a></li><li><a class="nounderline abstract_t">Levine GN, Bates ER, Blankenship JC, et al. 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. J Am Coll Cardiol 2016; 67:1235.</a></li><li><a class="nounderline abstract_t">Jolly SS, Cairns JA, Yusuf S, et al. Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med 2015; 372:1389.</a></li><li><a class="nounderline abstract_t">Fröbert O, Lagerqvist B, Olivecrona GK, et al. Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med 2013; 369:1587.</a></li><li><a class="nounderline abstract_t">Lagerqvist B, Fröbert O, Olivecrona GK, et al. Outcomes 1 year after thrombus aspiration for myocardial infarction. N Engl J Med 2014; 371:1111.</a></li><li><a class="nounderline abstract_t">Svilaas T, Vlaar PJ, van der Horst IC, et al. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med 2008; 358:557.</a></li><li><a class="nounderline abstract_t">Kumbhani DJ, Bavry AA, Desai MY, et al. Role of aspiration and mechanical thrombectomy in patients with acute myocardial infarction undergoing primary angioplasty: an updated meta-analysis of randomized trials. J Am Coll Cardiol 2013; 62:1409.</a></li><li><a class="nounderline abstract_t">Jolly SS, James S, Džavík V, et al. Thrombus Aspiration in ST-Segment-Elevation Myocardial Infarction: An Individual Patient Meta-Analysis: Thrombectomy Trialists Collaboration. Circulation 2017; 135:143.</a></li><li><a class="nounderline abstract_t">Burzotta F, De Vita M, Gu YL, et al. Clinical impact of thrombectomy in acute ST-elevation myocardial infarction: an individual patient-data pooled analysis of 11 trials. Eur Heart J 2009; 30:2193.</a></li><li><a class="nounderline abstract_t">Ali A, Cox D, Dib N, et al. Rheolytic thrombectomy with percutaneous coronary intervention for infarct size reduction in acute myocardial infarction: 30-day results from a multicenter randomized study. J Am Coll Cardiol 2006; 48:244.</a></li><li><a class="nounderline abstract_t">Migliorini A, Stabile A, Rodriguez AE, et al. Comparison of AngioJet rheolytic thrombectomy before direct infarct artery stenting with direct stenting alone in patients with acute myocardial infarction. The JETSTENT trial. J Am Coll Cardiol 2010; 56:1298.</a></li><li><a class="nounderline abstract_t">Kastrati A, Byrne RA, Schömig A. Is it time to jettison complex mechanical thrombectomy in favor of simple manual aspiration devices? J Am Coll Cardiol 2010; 56:1307.</a></li><li><a class="nounderline abstract_t">Stone GW, Webb J, Cox DA, et al. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. JAMA 2005; 293:1063.</a></li><li><a class="nounderline abstract_t">Gick M, Jander N, Bestehorn HP, et al. Randomized evaluation of the effects of filter-based distal protection on myocardial perfusion and infarct size after primary percutaneous catheter intervention in myocardial infarction with and without ST-segment elevation. Circulation 2005; 112:1462.</a></li><li><a class="nounderline abstract_t">Kelbaek H, Terkelsen CJ, Helqvist S, et al. Randomized comparison of distal protection versus conventional treatment in primary percutaneous coronary intervention: the drug elution and distal protection in ST-elevation myocardial infarction (DEDICATION) trial. J Am Coll Cardiol 2008; 51:899.</a></li><li><a class="nounderline abstract_t">Schömig A, Kastrati A. Distal embolic protection in patients with acute myocardial infarction: attractive concept but no evidence of benefit. JAMA 2005; 293:1116.</a></li><li><a class="nounderline abstract_t">Gorog DA, Foale RA, Malik I. Distal myocardial protection during percutaneous coronary intervention: when and where? J Am Coll Cardiol 2005; 46:1434.</a></li><li><a class="nounderline abstract_t">Limbruno U, De Caterina R. EMERALD, AIMI, and PROMISE: is there still a potential for embolic protection in primary PCI? Eur Heart J 2006; 27:1139.</a></li><li><a class="nounderline abstract_t">Stone GW, Maehara A, Witzenbichler B, et al. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA 2012; 307:1817.</a></li><li><a class="nounderline abstract_t">Aung Naing K, Li L, Su Q, Wu T. Adenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarction. Cochrane Database Syst Rev 2013; :CD009503.</a></li><li><a class="nounderline abstract_t">Lee CH, Wong HB, Tan HC, et al. Impact of reversibility of no reflow phenomenon on 30-day mortality following percutaneous revascularization for acute myocardial infarction-insights from a 1,328 patient registry. J Interv Cardiol 2005; 18:261.</a></li><li><a class="nounderline abstract_t">Hillegass WB, Dean NA, Liao L, et al. Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experience. J Am Coll Cardiol 2001; 37:1335.</a></li><li><a class="nounderline abstract_t">Wang HJ, Lo PH, Lin JJ, et al. Treatment of slow/no-reflow phenomenon with intracoronary nitroprusside injection in primary coronary intervention for acute myocardial infarction. Catheter Cardiovasc Interv 2004; 63:171.</a></li><li><a class="nounderline abstract_t">Barcin C, Denktas AE, Lennon RJ, et al. Comparison of combination therapy of adenosine and nitroprusside with adenosine alone in the treatment of angiographic no-reflow phenomenon. Catheter Cardiovasc Interv 2004; 61:484.</a></li><li><a class="nounderline abstract_t">Werner GS, Lang K, Kuehnert H, Figulla HR. Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction. Catheter Cardiovasc Interv 2002; 57:444.</a></li><li><a class="nounderline abstract_t">Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation 2000; 101:2154.</a></li><li><a class="nounderline abstract_t">Gu YL, Kampinga MA, Wieringa WG, et al. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial. Circulation 2010; 122:2709.</a></li><li><a class="nounderline abstract_t">Thiele H, Schindler K, Friedenberger J, et al. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation 2008; 118:49.</a></li><li><a class="nounderline abstract_t">Prati F, Capodanno D, Pawlowski T, et al. Local delivery versus intracoronary infusion of abciximab in patients with acute coronary syndromes. JACC Cardiovasc Interv 2010; 3:928.</a></li><li><a class="nounderline abstract_t">Sezer M, Oflaz H, Gören T, et al. Intracoronary streptokinase after primary percutaneous coronary intervention. N Engl J Med 2007; 356:1823.</a></li><li><a class="nounderline abstract_t">Berger PB, Ellis SG, Holmes DR Jr, et al. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. Circulation 1999; 100:14.</a></li><li><a class="nounderline abstract_t">Yamamuro A, Akasaka T, Tamita K, et al. Coronary flow velocity pattern immediately after percutaneous coronary intervention as a predictor of complications and in-hospital survival after acute myocardial infarction. Circulation 2002; 106:3051.</a></li><li><a class="nounderline abstract_t">Bolognese L, Carrabba N, Parodi G, et al. Impact of microvascular dysfunction on left ventricular remodeling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction. Circulation 2004; 109:1121.</a></li><li><a class="nounderline abstract_t">Gibson CM, Cannon CP, Murphy SA, et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 2000; 101:125.</a></li><li><a class="nounderline abstract_t">Stone GW, Peterson MA, Lansky AJ, et al. Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction. J Am Coll Cardiol 2002; 39:591.</a></li></ol></div><div id="topicVersionRevision">Topic 81 Version 34.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14642681" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical and angiographic correlates and outcomes of suboptimal coronary flow inpatients with acute myocardial infarction undergoing primary percutaneous coronary intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15988742" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Poor long-term patient and graft survival after primary percutaneous coronary intervention for acute myocardial infarction due to saphenous vein graft occlusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14981008" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Impaired myocardial perfusion is a major explanation of the poor outcome observed in patients undergoing primary angioplasty for ST-segment-elevation myocardial infarction and signs of heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15670542" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Relation between electrocardiographic ST-segment resolution and early and late outcomes after primary percutaneous coronary intervention for acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15913506" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Coronary No-reflow Phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11350105" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The coronary no-reflow phenomenon: a review of mechanisms and therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12090749" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15708696" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15904649" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Comparison of myocardial perfusion after successful primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction with versus without diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16198836" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Duration of ischemia is a major determinant of transmurality and severe microvascular obstruction after primary angioplasty: a study performed with contrast-enhanced magnetic resonance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9768709" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Assessment of "microvascular no-reflow phenomenon" using technetium-99m macroaggregated albumin scintigraphy in patients with acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11919304" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11028471" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8205658" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Incidence and treatment of 'no-reflow' after percutaneous coronary intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12651035" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Thrombolysis in myocardial infarction myocardial perfusion grade in angiography correlates with myocardial salvage in patients with acute myocardial infarction treated with stenting or thrombolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8640973" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11499740" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Predictive factors for development of the no-reflow phenomenon in patients with reperfused anterior wall acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1571929" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Reperfusion induced injury: manifestations, mechanisms, and clinical relevance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7418179" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Ultrastructural evidence of microvascular damage and myocardial cell injury after coronary artery occlusion: which comes first?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11929768" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9927393" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Alpha-adrenergic blockade improves recovery of myocardial perfusion and function after coronary stenting in patients with acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22421225" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Plaque composition by intravascular ultrasound and distal embolization after percutaneous coronary intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11997276" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12598061" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Prediction of clinical outcome after mechanical revascularization in acute myocardial infarction by markers of myocardial reperfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10421592" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Can coronary blood flow velocity pattern after primary percutaneous transluminal coronary angioplasty [correction of angiography] predict recovery of regional left ventricular function in patients with acute myocardial infarction?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8822979" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Alternation in the coronary blood flow velocity pattern in patients with no reflow and reperfused acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15557378" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Coronary blood flow assessment after successful angioplasty for acute myocardial infarction predicts the risk of long-term cardiac events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10821812" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Assessment of myocardial reperfusion by intravenous myocardial contrast echocardiography and coronary flow reserve after primary percutaneous transluminal coronary angioplasty [correction of angiography] in patients with acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15117844" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Detection of acutely impaired microvascular reperfusion after infarct angioplasty with magnetic resonance imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16386662" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Effects of primary angioplasty for acute myocardial infarction on early and late infarct size and left ventricular wall characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26498666" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25853743" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Randomized trial of primary PCI with or without routine manual thrombectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23991656" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Thrombus aspiration during ST-segment elevation myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25176395" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Outcomes 1 year after thrombus aspiration for myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18256391" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Thrombus aspiration during primary percutaneous coronary intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23665372" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Role of aspiration and mechanical thrombectomy in patients with acute myocardial infarction undergoing primary angioplasty: an updated meta-analysis of randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27941066" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Thrombus Aspiration in ST-Segment-Elevation Myocardial Infarction: An Individual Patient Meta-Analysis: Thrombectomy Trialists Collaboration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19726437" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Clinical impact of thrombectomy in acute ST-elevation myocardial infarction: an individual patient-data pooled analysis of 11 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16843170" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Rheolytic thrombectomy with percutaneous coronary intervention for infarct size reduction in acute myocardial infarction: 30-day results from a multicenter randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20691553" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Comparison of AngioJet rheolytic thrombectomy before direct infarct artery stenting with direct stenting alone in patients with acute myocardial infarction. The JETSTENT trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20691554" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Is it time to jettison complex mechanical thrombectomy in favor of simple manual aspiration devices?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15741528" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16129793" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Randomized evaluation of the effects of filter-based distal protection on myocardial perfusion and infarct size after primary percutaneous catheter intervention in myocardial infarction with and without ST-segment elevation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18308157" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Randomized comparison of distal protection versus conventional treatment in primary percutaneous coronary intervention: the drug elution and distal protection in ST-elevation myocardial infarction (DEDICATION) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15741535" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Distal embolic protection in patients with acute myocardial infarction: attractive concept but no evidence of benefit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16226166" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Distal myocardial protection during percutaneous coronary intervention: when and where?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16452101" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : EMERALD, AIMI, and PROMISE: is there still a potential for embolic protection in primary PCI?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22447888" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23736949" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Adenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16115155" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Impact of reversibility of no reflow phenomenon on 30-day mortality following percutaneous revascularization for acute myocardial infarction-insights from a 1,328 patient registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11300444" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15390241" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Treatment of slow/no-reflow phenomenon with intracoronary nitroprusside injection in primary coronary intervention for acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15065143" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Comparison of combination therapy of adenosine and nitroprusside with adenosine alone in the treatment of angiographic no-reflow phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12455077" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10801755" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21098442" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18559698" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20850091" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Local delivery versus intracoronary infusion of abciximab in patients with acute coronary syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17476008" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Intracoronary streptokinase after primary percutaneous coronary intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10393675" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12473550" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Coronary flow velocity pattern immediately after percutaneous coronary intervention as a predictor of complications and in-hospital survival after acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14967718" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Impact of microvascular dysfunction on left ventricular remodeling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10637197" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11849856" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
